The most common side effects with COVID-19 Vaccine Moderna were usually mild or moderate and got better within a few days after vaccination.

The high efficacy was also maintained across genders, racial and ethnic groups.ĬOVID-19 Vaccine Moderna is given as two injections into the arm, 28 days apart. The trial also showed 90.9% efficacy in participants at risk of severe COVID-19, including those with chronic lung disease, heart disease, obesity, liver disease, diabetes or HIV infection. This means that the vaccine demonstrated a 94.1% efficacy in the trial. The trial showed a 94.1% reduction in the number of symptomatic COVID-19 cases in the people who received the vaccine (11 out of 14,134 vaccinated people got COVID-19 with symptoms) compared with people who received dummy injections (185 out of 14,073 people who received dummy injections got COVID-19 with symptoms). People did not know whether they received the vaccine or the dummy injections.Įfficacy was calculated in around 28,000 people from 18 to 94 years of age who had no sign of previous infection. Half received the vaccine and half were given dummy injections. The trial involved around 30,000 people in total.

Our work will always be guided by the scientific evidence and our commitment to safeguard the health of EU citizens.”Ī very large clinical trial showed that COVID-19 Vaccine Moderna was effective at preventing COVID-19 in people from 18 years of age. “As for all medicines, we will closely monitor data on the safety and effectiveness of the vaccine to ensure ongoing protection of the EU public. “It is a testament to the efforts and commitment of all involved that we have this second positive vaccine recommendation just short of a year since the pandemic was declared by WHO. “This vaccine provides us with another tool to overcome the current emergency,” said Emer Cooke, Executive Director of EMA. This will assure EU citizens that the vaccine meets EU standards and puts in place the safeguards, controls and obligations to underpin EU-wide vaccination campaigns. This is the second COVID-19 vaccine that EMA has recommended for authorisation.ĮMA’s human medicines committee ( CHMP) has thoroughly assessed the data on the quality, safety and efficacy of the vaccine and recommended by consensus a formal conditional marketing authorisation be granted by the European Commission. This follows the granting of a conditional marketing authorisation by the European Commission on 6 January 2021.ĮMA has recommended granting a conditional marketing authorisation for COVID-19 Vaccine Moderna to prevent Coronavirus disease (COVID-19) in people from 18 years of age. COVID-19 Vaccine Moderna is now authorised across the EU.

Eu4 modern day mod